News & Press

We are pleased that after the long COVID lockdown we were able to conduct a QFT workshop in Nairobi in person.

From 20th to 21st of June 2022, VPM organized the priMe annual meeting, finally
in person again, in Mombasa, Kenya.

We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.

We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.

March 24 is the World Tuberculosis (TB) day! The theme of 2022: “Invest to End TB. Save Lives.”

VPM and Serum Institute of India Pvt. Ltd. are developing VPM1002 as a novel vaccine to protect against TB.
We collaborate in the pivotal phase III trial (priMe) with clinical partners in five Sub-Saharan African countries,
as well as with European partners for one specific goal: #EndTB. The project is funded by European & Developing Countries
Clinical Trials Partnership and European Investment Bank.
We hope for a world free of TB!